...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

ProBioGen and Inhibrx Sign License Deal on GlymaxX ADCC Technology for Therapeutic Antibodies Development

| Print |
Tuesday, 25 October 2011 10:00 (UTC + 2)
Inhibrx_Logo ProBioGen_logo

Berlin, Germany and San Diego, California, USA, October 25, 2011 / B3C newswire / – ProBioGen and Inhibrx signed a multi-program license deal on ADCC-enhanced therapeutic antibodies. ProBioGen’s GlymaxX® ADCC enhancement technology and mammalian cell line development and manufacturing services will be used to advance therapeutic antibodies generated by Inhibrx’s discovery platforms.

The agreement initially covers development services for several undisclosed first-in-class and best-in-class antibodies with enhanced ADCC potency, as well as cell line and process development for other recombinant therapeutic proteins. ProBioGen will receive both milestone-dependent license fees, as well as fee-for-service-based payments for its technologies and efforts. Further financial details were not disclosed.

"We are impressed with Inhibrx’s discovery platforms and their target selection expertise. This effort is a perfect match for the two companies’ complementary core expertise, enabling industrial discovery and development of a range of innovative therapeutic proteins” explained ProBioGen’s Chief Scientific Officer, Dr Volker Sandig. Dr Wieland Wolf, CEO added “Inhibrx’s company culture is very similar to ours, pragmatic, technology and science-driven with the aim to leverage proprietary technologies and expertise. We are looking very much forward working together in this spirit.”

Mark Lappe, CEO of Inhibrx said “We were searching for one company with proven cell line development, process and cell line based ADCC enhancement technologies. ProBioGen’s time tested expertise and innovative culture have created what we consider to be the perfect combination of technologies for deriving the most value and competitive edge for our therapeutic antibody and biologic programs.”


About ProBioGen
ProBioGen is an internationally operating Contract Development and Manufacturing Organization (CDMO) with almost 20 years of experience in mammalian cell culture, process development and GMP-manufacturing. ProBioGen, with its scientific excellence and strong intellectual property base, is a competent and reliable CDMO partner, offering customized solutions for even the most challenging development and manufacturing requirements. This is backed by the companies’ established, fee-for-service-based CHO cell and media platform, its GlymaxX® ADCC enhancement technology and its AGE1® family of animal and human designer cell lines. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994 and is located in Berlin, Germany.

About Inhibrx
Inhibrx is a biotherapeutics discovery and development company, founded to meet the strategic needs of pharmaceutical companies to cost effectively and predictably build a pipeline of innovative therapeutic antibodies and biologics. Inhibrx has an extensive internally developed biotherapeutics pipeline, with programs focused on cancer, inflammatory and metabolic diseases. The Inhibrx business model allows early risk sharing with pharmaceutical partners and creatively implements multiple strategies and platforms to enhance program success rates, achieve rapid execution and produce optimal clinical candidates.

Inhibrx is located in La Jolla, CA.

About GlymaxX®
The GlymaxX® technology, developed by ProBioGen prevents the addition of the sugar “fucose” to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose enhances ADCC. The GlymaxX® technology is based on the introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. The GlymaxX® technology is universally applicable to different CHO hosts and to any other eukaryotic cell line; it is also simple and potent. GlymaxX® can be applied in a few weeks to any existing antibody producer cell line, or can be included into any new cell line development. ProBioGen offers this technology royalty-free to third parties.


Contact ProBioGen
Dr Gabriele Schneider
Vice President Business Development
ProBioGen AG
Goethestrasse 54
13086 Berlin
Phone.: +49 (0)30 924 006-0
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.probiogen.de
www.glymaxx.com

Contact Inhibrx
Mark Lappe
CEO
Inhibrx LLC
11099 N. Torrey Pines Road, Suite 130
La Jolla, CA 92037
Phone: (858) 759-1499
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it